In a study published in Cancer Immunology Research, researchers at Moffitt Cancer Center, led by Amer A. Beg, show how stimulating dendritic cells through the CD40 and interferon β pathways produces strong T-cell activity against tumors and works in conjunction with immune checkpoint inhibitors to produce even stronger responses.
Researchers at Moffitt Cancer Center have published a case study highlighting the potential optimization of the TAMP, or trans-arterial micro-perfusion, procedure with RenovoCath to deliver intra-arterial gemcitabine (a commonly used chemotherapy) directly near a tumor (rather than traditional systemic IV administration) in a patient with locally advanced pancreatic cancer.
